108
Views
11
CrossRef citations to date
0
Altmetric
Research Articles

Poly-β-Cyclodextrin-coated neodymium-containing copper sulphide nanoparticles as an effective anticancer drug carrier

, , , , & ORCID Icon
Pages 409-418 | Received 26 Feb 2022, Accepted 20 Jun 2022, Published online: 07 Jul 2022
 

Abstract

This study aims at tuning the properties of the nanoparticles by incorporating neodymium, exploring the sustained release of drug, and the anticancer activity on breast cancer cells. The crystal characteristics of NdCuS2 nanoparticles are analysed using X-ray diffraction. The morphology and size of the nanoparticles were characterised using Transmission Electron Microscope and particle size analyser. The rate of release of the encapsulated camptothecin and anticancer effects on breast cancer cells are investigated. The nanoparticles are rod-shaped, 132 ± 8 nm long and 27 ± 7 nm wide. The band gap of the nanoparticles is 4.85 eV. The drug encapsulation efficiency is 94.76% (w/w). The drug is released in a sustained manner, over a period of 180 h. The cytotoxicity of the camptothecin-loaded NPs is examined on MDA-MB-231 cells and the IC50 is 4.39 µg mL−1. The NdCuS2 nanoparticles are promising as theranostic agents considering their material characteristics and anticancer activity.

Acknowledgements

The authors thank the management of KITS for providing the necessary facilities.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.